SCMC SYRUP 100 100mg/5ml

Product Information

Registration Status: Active

SCMC SYRUP 100 100mg/5ml is approved to be sold in Singapore with effective from 1989-05-22. It is marketed by BEACONS PHARMACEUTICALS PTE LTD, with the registration number of SIN02852P.

This product contains Carbocisteine 100mg/5ml in the form of SYRUP. It is approved for ORAL use.

This product is manufactured by BEACONS PHARMACEUTICALS PTE LTD in SINGAPORE.

It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.



Carbocisteine is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine should not be used with antitussives (cough suppressants) or medicines that dry up bronchial secretions. Carbocisteine is produced by alkylation of cysteine with chloroacetic acid.


Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis.

Active Ingredient/Synonyms

(L)-2-Amino-3-(carboxymethylthio)propionic acid | (R)-S-(carboxymethyl)cysteine | L-3-((carboxymethyl)thio)alanine | L-carbocysteine | S-(carboxymethyl)-(R)-cysteine | S-carboxymethyl-L-cysteine | S-carboxymethylcysteine | Carbocisteine |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank